This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies | MicrobiomeTrials
← Back to trials NCT06904066
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies Recruiting PHASE1 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-06-14Est. Completion: 2029-04-30
Enrollment target: 86 participantsLocations National Institutes of Health Clinical Center, Bethesda, Maryland, United States Other microbiome trials you might be interested in Healthy Donors
Background
-NCI-Frederick scientists performing in vitro studies involving human specimens have a need for a reliable a…
Frederick, United States Completed Oct 1, 2030
Myeloma Multiple
The BELAMI trial is an open label, multicenter, phase 2 study for patients with MM who relapsed following BCMA-directed …
Amiens, France Est. completion Jan 1, 2028
SUSPENDED
Multiple Myeloma Relapsed and/or Refractory Multiple Myeloma (RRMM)
Background:
Multiple myeloma (MM) is a type of blood cancer that affects a person s immunity. MM returns after treatmen…
Bethesda, United States Completed Jan 1, 2033